Early access
Sign in
Not yet recruitingPhase 4

Inhaled antibiotics for adults with bronchiectasis and long-lasting lung infection

Tests inhaled antibiotics against placebo in adults with bronchiectasis and chronic bronchial infection.

Key facts

Who runs it
Consorci Mar Parc De Salut De Barcelona
Where
Spain1 site in 1 countryChoose a country to see its sites
Registry title
PHARMACOLOGICAL STRATEGIES OF INHALED ANTIBIOTHERAPY IN BRONCHIECTASIS WITH CHRONIC BRONCHIAL INFECTION: BRONCHIPHARMA STUDY.
Status
Not yet recruiting
Phase
Phase 4
People taking part
75 people, planned
Started
2 May 2024
Planned end
1 Mar 2026
Type of study
Interventional
Record updated
3 June 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with bronchiectasis (widened airways) and a long-lasting chest infection. It tests inhaled antibiotics against placebo after oral or intravenous treatment.

Age
20 to 90 years (the record also lists a minimum age of 18 Years)
Sex
Men and women can join.
Disease stage
Bronchiectasis with chronic bronchial infection. Severity is rated with the BSI, FACED and EFACED scales. People must be followed by the Multidisciplinary Bronchiectasis Unit of Hospital del Mar.
Earlier treatment
No inhaled or nebulized antibiotics in the last year. People can join whatever their other treatment, such as inhaled corticosteroids, bronchodilators, azithromycin or respiratory physiotherapy.
Biomarker or test result
At least 2 sputum cultures positive for the same germ in the last year.

Main reasons for not taking part

  • Bad reactions to inhaled or nebulized antibiotics
  • Unable to use the nebulizer device
  • Long-term oxygen therapy at home
  • Infection with nontuberculous mycobacteria at the same time
  • Positive pregnancy test or wish to become pregnant during the study

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adult patients with bronchiectasis
  • Age 20 to 90 years
  • Men and women alike
  • Minimum of 2 sputum cultures positive for the same germ in the last year
  • Under follow-up by the Multidisciplinary Bronchiectasis Unit of Hospital del Mar
  • Severity of bronchiectasis and exacerbations according to the current scales: BSI, FACED, EFACED
  • All patients who meet these criteria will be included regardless of their background treatment: Inhaled corticosteroids, bronchodilators, concomitant treatment with oral antibiotics such as azithromycin and whether or not they are receiving respiratory physiotherapy
  • Provide signed and dated informed consent form
  • Be willing to comply with all study procedures and be available during the duration of the study

Who cannot take part

  • Inhaled/nebulized antibiotic therapy in the last year
  • Carriers of chronic home oxygen therapy
  • Concomitant infection with nontuberculous mycobacteria
  • In the case of women of childbearing age, a positive pregnancy test or desire for pregnancy during the period of the study
  • Adverse reactions to inhaled/nebulized antibiotics
  • Inability to use the nebulization device

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate if patients with chronic bronchial infection after receiving a course of targeted oral or intravenous treatment who subsequently receive treatment with inhaled antibiotics have a reduction in the colony-forming units compared to the placebo group.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
PHARMACOLOGICAL STRATEGIES OF INHALED ANTIBIOTHERAPY IN BRONCHIECTASIS WITH CHRONIC BRONCHIAL INFECTION: BRONCHIPHARMA STUDY.
Plain-language title
Inhaled antibiotics for adults with bronchiectasis and long-lasting lung infectionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
3 June 2024